Marchiafava-Bignami Disease

Neurological Disorder MONDO:0016370 Pathograph 9 demyelinating disease of central nervous system

Marchiafava-Bignami disease is a rare acquired toxic-metabolic neurologic disorder, usually associated with chronic alcohol use and malnutrition, in which central nervous system myelin degeneration and necrosis preferentially injure the corpus callosum and sometimes adjacent white matter.

Ask OpenScientist

Ask a research question about Marchiafava-Bignami Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

6
Pathophys.
9
Phenotypes
9
Pathograph
3
Treatments
2
Subtypes
8
References
1
Deep Research
◆

Subtypes

2
Heinrich type A acute Marchiafava-Bignami disease
Acute MBD subtype with entire corpus callosum involvement; cohort data indicate clinico-radiologic type relates to early symptom severity but not final prognosis.
Show evidence (2 references)
DOI:10.1038/s41598-023-45431-6 SUPPORT Human Clinical
"The clinical and MRI data of 23 patients with acute MBD were retrospectively analyzed and divided into type A (12 cases, with entire callosal involvement) and type B (11 cases, with focal callosal involvement)."
The retrospective cohort defines type A by entire callosal involvement.
DOI:10.1038/s41598-023-45431-6 SUPPORT Human Clinical
"Clinico-radiologic typing of acute MBD is related to the severity of early symptoms, but not to the prognosis."
The cohort supports type A as a clinico-radiologic subtype tied to early severity rather than final prognosis.
Heinrich type B acute Marchiafava-Bignami disease
Acute MBD subtype with focal corpus callosum involvement; cohort data indicate clinico-radiologic type relates to early symptom severity but not final prognosis.
Show evidence (2 references)
DOI:10.1038/s41598-023-45431-6 SUPPORT Human Clinical
"The clinical and MRI data of 23 patients with acute MBD were retrospectively analyzed and divided into type A (12 cases, with entire callosal involvement) and type B (11 cases, with focal callosal involvement)."
The retrospective cohort defines type B by focal callosal involvement.
DOI:10.1038/s41598-023-45431-6 SUPPORT Human Clinical
"Clinico-radiologic typing of acute MBD is related to the severity of early symptoms, but not to the prognosis."
The cohort supports type B as a clinico-radiologic subtype tied to early severity rather than final prognosis.
⚙

Pathophysiology

6
Impaired myelin synthesis and signal transmission
Metabolic disruption hinders myelin synthesis and impairs signal transmission through affected callosal fibers.
axon ensheathment link ↓ DECREASED
myelin sheath link
corpus callosum link
Downstream
Cytotoxic edema in callosal white matter Impaired myelin and energy metabolism contribute to acute callosal cytotoxic edema.
Show evidence (1 reference)
PMID:37559750 SUPPORT Human Clinical
"This, in turn, hinders myelin synthesis and impairs signal transmission, resulting in a wide range of symptoms and signs."
The review links metabolic disruption to impaired myelin synthesis and signal transmission.
Cytotoxic edema in callosal white matter
Acute metabolic injury can produce restricted diffusion consistent with cytotoxic edema in corpus callosum white matter before progression to demyelination and necrosis.
corpus callosum link
Downstream
Callosal myelin degeneration and necrosis Persistent cytotoxic edema and metabolic injury can progress to demyelination and necrosis.
Show evidence (2 references)
DOI:10.15744/2454-4981.3.201 SUPPORT Human Clinical
"Areas of restricted diffusion on DWI (acute phase) | Cytotoxic edema"
The imaging-pathophysiology table maps acute DWI restricted diffusion to cytotoxic edema.
PMID:37559750 PARTIAL Human Clinical
"MRI-diffusion-weighted imaging (DWI) detects early lesions, while diffusion tensor imaging (DTI) investigates clinical manifestations and recovery."
The review supports DWI as the modality for detecting early lesions that correspond to the cytotoxic edema stage.
Callosal myelin degeneration and necrosis
Myelin degeneration and necrosis preferentially affect the corpus callosum, producing the characteristic lesion of Marchiafava-Bignami disease.
oligodendrocyte link
myelin sheath link
corpus callosum link
Downstream
Extracallosal white matter involvement More extensive toxic-metabolic injury can extend beyond the corpus callosum.
Interhemispheric disconnection syndrome Callosal fiber injury can produce interhemispheric disconnection signs.
Show evidence (2 references)
PMID:37559750 SUPPORT Human Clinical
"Marchiafava Bignami disease (MBD) is a neurological disorder characterized by myelin degeneration and tissue necrosis within the central nervous system."
The review defines MBD by central nervous system myelin degeneration and necrosis.
PMID:37559750 SUPPORT Human Clinical
"The most distinctive pathological feature of MBD is the necrotic degeneration specifically observed in the corpus callosum; however, emerging evidence also indicates the potential involvement of other brain regions."
The quote identifies necrotic degeneration of the corpus callosum as the distinctive pathology.
Extracallosal white matter involvement
Lesions may extend outside the corpus callosum into adjacent or distant central nervous system white matter, and a broader lesion burden is a poor prognostic sign.
myelin sheath link
central nervous system white matter link
Show evidence (1 reference)
PMID:39402444 SUPPORT Human Clinical
"Lesions might also involve white matter outside the corpus callosum, and a wider range of lesions suggested a poor prognosis."
The 33-case clinical analysis supports extracallosal lesion involvement and its prognostic implication.
Interhemispheric disconnection syndrome
Injury to corpus callosum fibers can impair interhemispheric transfer and contribute to disconnection signs, language disturbance, cognition changes, and motor manifestations.
neuron link
corpus callosum link
Show evidence (1 reference)
PMID:33303506 SUPPORT Human Clinical
"The clinical presentation is varied and non-specific, including symptoms of acute dementia, impaired consciousness, dysarthria, hemiparesis, pyramidal tract signs, seizure activity, ataxia and signs of interhemispheric disconnection."
The case-report abstract lists interhemispheric disconnection signs among MBD manifestations.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Marchiafava-Bignami Disease Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

9
Nervous System 8
Speech disorder Dysarthria (HP:0001260)
Show evidence (2 references)
PMID:39402444 SUPPORT Human Clinical
"Based on our analysis, we found that MBD primarily affects middle-aged men and typically has an acute or subacute onset, with the primary clinical manifestations being disturbances of consciousness, speech disorders, cognitive impairment, and psychiatric or behavioral abnormalities, often..."
The case synthesis identifies speech disorders as a primary clinical manifestation.
PMID:33303506 SUPPORT Human Clinical
"The clinical presentation is varied and non-specific, including symptoms of acute dementia, impaired consciousness, dysarthria, hemiparesis, pyramidal tract signs, seizure activity, ataxia and signs of interhemispheric disconnection."
The case-report abstract specifically lists dysarthria.
Aphasia Aphasia (HP:0002381)
Show evidence (1 reference)
PMID:39650996 PARTIAL Human Clinical
"We report a case of MDB that was diagnosed in a 43-year-old woman with a history of chronic alcohol use and a 15-day history of progressive neurological symptoms, including impaired speech, confusion, and inability to walk independently."
The abstract supports impaired speech, which may include aphasic or dysarthric presentations.
Cognitive impairment Cognitive impairment (HP:0100543)
Show evidence (2 references)
PMID:39402444 SUPPORT Human Clinical
"Based on our analysis, we found that MBD primarily affects middle-aged men and typically has an acute or subacute onset, with the primary clinical manifestations being disturbances of consciousness, speech disorders, cognitive impairment, and psychiatric or behavioral abnormalities, often..."
The case synthesis identifies cognitive impairment as a primary manifestation.
PMID:39650996 SUPPORT Human Clinical
"The condition often presents with cognitive dysfunction, motor deficits, and altered consciousness, which can range from mild confusion to severe stupor."
The case-report abstract describes cognitive dysfunction as a common presentation.
Psychiatric or behavioral abnormality Atypical behavior (HP:0000708)
Show evidence (1 reference)
PMID:39402444 SUPPORT Human Clinical
"Based on our analysis, we found that MBD primarily affects middle-aged men and typically has an acute or subacute onset, with the primary clinical manifestations being disturbances of consciousness, speech disorders, cognitive impairment, and psychiatric or behavioral abnormalities, often..."
The case synthesis directly identifies psychiatric or behavioral abnormalities.
Ataxia Ataxia (HP:0001251)
Show evidence (1 reference)
PMID:33303506 SUPPORT Human Clinical
"The clinical presentation is varied and non-specific, including symptoms of acute dementia, impaired consciousness, dysarthria, hemiparesis, pyramidal tract signs, seizure activity, ataxia and signs of interhemispheric disconnection."
The case-report abstract lists ataxia among MBD manifestations.
Hemiparesis Hemiparesis (HP:0001269)
Show evidence (1 reference)
PMID:33303506 SUPPORT Human Clinical
"The clinical presentation is varied and non-specific, including symptoms of acute dementia, impaired consciousness, dysarthria, hemiparesis, pyramidal tract signs, seizure activity, ataxia and signs of interhemispheric disconnection."
The case-report abstract lists hemiparesis among MBD manifestations.
Seizure Seizure (HP:0001250)
Show evidence (1 reference)
PMID:33303506 SUPPORT Human Clinical
"The clinical presentation is varied and non-specific, including symptoms of acute dementia, impaired consciousness, dysarthria, hemiparesis, pyramidal tract signs, seizure activity, ataxia and signs of interhemispheric disconnection."
The case-report abstract lists seizure activity among MBD manifestations.
Apraxia Apraxia (HP:0002186)
Show evidence (2 references)
DOI:10.1186/s12883-024-03901-y SUPPORT Human Clinical
"Other clinical manifestations included emotional or personality changes (10 cases, 30.3%), seizures (4 cases, 12.1%), sensory disturbances (3 cases), neglect (2 cases), corpus callosum disconnection (2 cases), apraxia (4 cases), and combined neglect and apraxia (1 case)."
The 33-case synthesis reports apraxia in 4 cases and combined neglect/apraxia in 1 additional case.
PMID:34473675 SUPPORT Human Clinical
"Here, we report a man with probable MBD with callosal and right medial paracentral lesions who presented with abnormal reaching behavior and ideomotor apraxia of the left hand."
The case-report abstract directly documents ideomotor apraxia in probable MBD.
Other 1
Reduced consciousness Reduced consciousness (HP:0004372)
Show evidence (2 references)
PMID:39402444 SUPPORT Human Clinical
"Based on our analysis, we found that MBD primarily affects middle-aged men and typically has an acute or subacute onset, with the primary clinical manifestations being disturbances of consciousness, speech disorders, cognitive impairment, and psychiatric or behavioral abnormalities, often..."
The case synthesis identifies disturbances of consciousness as a primary clinical manifestation.
PMID:39791092 SUPPORT Human Clinical
"A 27-year-old male patient with chronic alcohol use disorder was diagnosed with Marchiafava-Bignami disease (MBD) after experiencing an episode of unconsciousness."
The case report documents unconsciousness at presentation.
💊

Treatments

3
Parenteral thiamine and B-vitamin repletion
Action: Pharmacotherapy NCIT:C15986
Agent: vitamin B1 ↗
Prompt high-dose thiamine and B-vitamin replacement is the primary disease-directed treatment because thiamine depletion is a central mechanism and delayed therapy worsens outcomes.
Mechanism Target:
Alcohol-related thiamine depletion — Thiamine replacement addresses the deficiency-associated upstream driver.
Impaired myelin synthesis and signal transmission — Vitamin repletion is intended to support restoration of myelin metabolism.
Show evidence (3 references)
PMID:37559750 SUPPORT Human Clinical
"Notably, thiamine treatment reduces the likelihood of unfavorable consequences, particularly when administered promptly, and thus is endorsed as the primary therapeutic approach for MBD."
The review supports prompt thiamine as the primary therapeutic approach.
PMID:39650996 SUPPORT Human Clinical
"The patient was treated with high-dose intravenous thiamine and B vitamins, resulting in a gradual and significant improvement."
The case report directly supports clinical improvement after high-dose intravenous thiamine and B vitamins.
PMID:33303506 SUPPORT Human Clinical
"Administration of thiamine within 14 days of symptom onset has demonstrated statistically better outcomes over delayed treatment."
The case-report abstract supports early thiamine treatment.
Adjunct corticosteroid therapy
Action: Pharmacotherapy NCIT:C15986
Agent: corticosteroid ↗
Corticosteroids are sometimes used as adjunctive therapy for edema, demyelination, and inflammation, but evidence is heterogeneous and often confounded by concurrent vitamin treatment.
Mechanism Target:
Callosal myelin degeneration and necrosis — Corticosteroids are used to address edema, demyelination, and inflammation around lesions.
Cytotoxic edema in callosal white matter — Corticosteroids are used as adjunctive therapy for edema around acute lesions.
Show evidence (2 references)
PMID:37559750 PARTIAL Human Clinical
"Corticosteroids offer prospective advantages in addressing brain edema, demyelination, and inflammation; research findings present a heterogeneous outcome pattern."
The review supports a plausible adjunctive role but explicitly notes heterogeneous outcomes.
PMID:39791092 PARTIAL Human Clinical
"Despite prompt initiation of intensive treatment with high-dose thiamine and corticosteroids, the patient only partially recovered, remaining disoriented and exhibiting persistent neurological deficits during follow-up."
This case documents corticosteroid use with only partial recovery, supporting a cautious PARTIAL classification.
Rehabilitation therapy and multidisciplinary supportive care
Action: supportive care MAXO:0000950
Rehabilitation and multidisciplinary supportive care may be used alongside vitamin repletion and pharmacotherapy to address gait, speech, and functional deficits during recovery.
Mechanism Target:
Interhemispheric disconnection syndrome — Rehabilitation addresses downstream functional deficits from callosal injury.
Show evidence (1 reference)
DOI:10.51338/rppsm.2020.v6.i1.120 SUPPORT Human Clinical
"He received thiamine, corticosteroids and rehabilitation."
The case-report abstract documents rehabilitation as part of multidisciplinary treatment.
🌍

Environmental Factors

1
Chronic alcohol use and malnutrition
Chronic alcohol exposure and malnutrition are the major recurring clinical contexts for Marchiafava-Bignami disease.
Show evidence (2 references)
PMID:39402444 SUPPORT Human Clinical
"Most patients have a history of alcohol consumption or malnutrition."
The 33-case analysis identifies alcohol consumption and malnutrition as common histories.
PMID:37559750 SUPPORT Human Clinical
"This condition predominantly afflicts individuals with chronic alcohol abuse and malnutrition."
The review identifies chronic alcohol abuse and malnutrition as the dominant clinical context.
{ }

Source YAML

click to show 
name: Marchiafava-Bignami Disease
creation_date: "2026-05-06T17:23:56Z"
updated_date: "2026-05-06T17:48:08Z"
description: >-
  Marchiafava-Bignami disease is a rare acquired toxic-metabolic neurologic
  disorder, usually associated with chronic alcohol use and malnutrition, in
  which central nervous system myelin degeneration and necrosis preferentially
  injure the corpus callosum and sometimes adjacent white matter.
category: Neurological Disorder
parents:
- demyelinating disease of central nervous system
disease_term:
  preferred_term: Marchiafava-Bignami disease
  term:
    id: MONDO:0016370
    label: Marchiafava-Bignami disease
synonyms:
- Marchiafava Bignami disease
- MBD
has_subtypes:
- name: Heinrich type A acute Marchiafava-Bignami disease
  classification: clinico-radiologic
  description: >-
    Acute MBD subtype with entire corpus callosum involvement; cohort data
    indicate clinico-radiologic type relates to early symptom severity but not
    final prognosis.
  evidence:
  - reference: DOI:10.1038/s41598-023-45431-6
    reference_title: Clinico-radiologic subtypes and therapeutic observation of acute Marchiafava-Bignami disease
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The clinical and MRI data of 23 patients with acute MBD were retrospectively analyzed and divided into type A (12 cases, with entire callosal involvement) and type B (11 cases, with focal callosal involvement).
    explanation: The retrospective cohort defines type A by entire callosal involvement.
  - reference: DOI:10.1038/s41598-023-45431-6
    reference_title: Clinico-radiologic subtypes and therapeutic observation of acute Marchiafava-Bignami disease
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinico-radiologic typing of acute MBD is related to the severity of early symptoms, but not to the prognosis.
    explanation: The cohort supports type A as a clinico-radiologic subtype tied to early severity rather than final prognosis.
- name: Heinrich type B acute Marchiafava-Bignami disease
  classification: clinico-radiologic
  description: >-
    Acute MBD subtype with focal corpus callosum involvement; cohort data
    indicate clinico-radiologic type relates to early symptom severity but not
    final prognosis.
  evidence:
  - reference: DOI:10.1038/s41598-023-45431-6
    reference_title: Clinico-radiologic subtypes and therapeutic observation of acute Marchiafava-Bignami disease
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The clinical and MRI data of 23 patients with acute MBD were retrospectively analyzed and divided into type A (12 cases, with entire callosal involvement) and type B (11 cases, with focal callosal involvement).
    explanation: The retrospective cohort defines type B by focal callosal involvement.
  - reference: DOI:10.1038/s41598-023-45431-6
    reference_title: Clinico-radiologic subtypes and therapeutic observation of acute Marchiafava-Bignami disease
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinico-radiologic typing of acute MBD is related to the severity of early symptoms, but not to the prognosis.
    explanation: The cohort supports type B as a clinico-radiologic subtype tied to early severity rather than final prognosis.
references:
- reference: DOI:10.15190/d.2023.7
  title: Diagnosis and Management of Marchiafava-Bignami Disease, a Rare Neurological Complication of Long-term Alcohol Abuse
  found_in:
  - Marchiafava_Bignami_Disease-deep-research-falcon.md
- reference: DOI:10.1186/s12883-024-03901-y
  title: Clinical analysis of Marchiafava-Bignami disease
  found_in:
  - Marchiafava_Bignami_Disease-deep-research-falcon.md
- reference: DOI:10.7759/cureus.73146
  title: "Marchiafava-Bignami Disease: A Case Report of a Reversible Cause of Dementia"
  found_in:
  - Marchiafava_Bignami_Disease-deep-research-falcon.md
- reference: DOI:10.1038/s41598-023-45431-6
  title: Clinico-radiologic subtypes and therapeutic observation of acute Marchiafava-Bignami disease
  found_in:
  - Marchiafava_Bignami_Disease-deep-research-falcon.md
- reference: DOI:10.1177/0284185120943040
  title: Diverse MRI findings and clinical outcomes of acute Marchiafava-Bignami disease
  found_in:
  - Marchiafava_Bignami_Disease-deep-research-falcon.md
- reference: DOI:10.1136/bcr-2020-238187
  title: Rare case of Marchiafava-Bignami disease due to thiamine deficiency and malnutrition
  found_in:
  - Marchiafava_Bignami_Disease-deep-research-falcon.md
- reference: DOI:10.7759/cureus.75468
  title: "An Atypical Case of Marchiafava-Bignami Disease in a Young Chronic Alcoholic: Challenges in Diagnosis and Prognosis"
  found_in:
  - Marchiafava_Bignami_Disease-deep-research-falcon.md
- reference: DOI:10.15744/2454-4981.3.201
  title: The Importance of Brain MRI in the Diagnosis of Marchiafava-Bignami Disease
  found_in:
  - Marchiafava_Bignami_Disease-deep-research-falcon.md
progression:
- phase: Acute, subacute, or chronic onset
  notes: >-
    Contemporary case synthesis supports acute, subacute, and chronic onset
    patterns, with acute onset most common among the 33 analyzed cases.
  evidence:
  - reference: DOI:10.1186/s12883-024-03901-y
    reference_title: Clinical analysis of Marchiafava-Bignami disease
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There were 18 cases (54.5%) with acute onset, 7 cases (21.2%) with subacute onset, and 8 cases (24.2%) with chronic onset.
    explanation: The 33-case synthesis provides the acute, subacute, and chronic onset distribution.
pathophysiology:
- name: Alcohol-related thiamine depletion
  description: >-
    Chronic alcohol exposure and malnutrition can deplete thiamine and disrupt
    metabolic pathways required for maintaining callosal myelin.
  chemical_entities:
  - preferred_term: vitamin B1
    modifier: DECREASED
    term:
      id: CHEBI:26948
      label: vitamin B1
  biological_processes:
  - preferred_term: myelination
    modifier: DECREASED
    term:
      id: GO:0042552
      label: myelination
  evidence:
  - reference: PMID:37559750
    reference_title: "Diagnosis and Management of Marchiafava-Bignami Disease, a Rare Neurological Complication of Long-term Alcohol Abuse."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The main pathophysiological mechanisms involve alcohol consumption, which leads to thiamine depletion and disrupts various metabolic pathways.
    explanation: The review identifies alcohol-related thiamine depletion and metabolic disruption as central mechanisms.
  downstream:
  - target: Impaired myelin synthesis and signal transmission
    description: Thiamine depletion and metabolic disruption reduce myelin synthesis and signal transmission.
- name: Impaired myelin synthesis and signal transmission
  description: >-
    Metabolic disruption hinders myelin synthesis and impairs signal
    transmission through affected callosal fibers.
  locations:
  - preferred_term: corpus callosum
    term:
      id: UBERON:0002336
      label: corpus callosum
  cellular_components:
  - preferred_term: myelin sheath
    modifier: DECREASED
    term:
      id: GO:0043209
      label: myelin sheath
  biological_processes:
  - preferred_term: axon ensheathment
    modifier: DECREASED
    term:
      id: GO:0008366
      label: axon ensheathment
  evidence:
  - reference: PMID:37559750
    reference_title: "Diagnosis and Management of Marchiafava-Bignami Disease, a Rare Neurological Complication of Long-term Alcohol Abuse."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This, in turn, hinders myelin synthesis and impairs signal transmission, resulting in a wide range of symptoms and signs.
    explanation: The review links metabolic disruption to impaired myelin synthesis and signal transmission.
  downstream:
  - target: Cytotoxic edema in callosal white matter
    description: Impaired myelin and energy metabolism contribute to acute callosal cytotoxic edema.
- name: Cytotoxic edema in callosal white matter
  description: >-
    Acute metabolic injury can produce restricted diffusion consistent with
    cytotoxic edema in corpus callosum white matter before progression to
    demyelination and necrosis.
  locations:
  - preferred_term: corpus callosum
    term:
      id: UBERON:0002336
      label: corpus callosum
  evidence:
  - reference: DOI:10.15744/2454-4981.3.201
    reference_title: The Importance of Brain MRI in the Diagnosis of Marchiafava-Bignami Disease
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Areas of restricted diffusion on DWI (acute phase) | Cytotoxic edema
    explanation: The imaging-pathophysiology table maps acute DWI restricted diffusion to cytotoxic edema.
  - reference: PMID:37559750
    reference_title: "Diagnosis and Management of Marchiafava-Bignami Disease, a Rare Neurological Complication of Long-term Alcohol Abuse."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      MRI-diffusion-weighted imaging (DWI) detects early lesions, while diffusion tensor imaging (DTI) investigates clinical manifestations and recovery.
    explanation: The review supports DWI as the modality for detecting early lesions that correspond to the cytotoxic edema stage.
  downstream:
  - target: Callosal myelin degeneration and necrosis
    description: Persistent cytotoxic edema and metabolic injury can progress to demyelination and necrosis.
- name: Callosal myelin degeneration and necrosis
  description: >-
    Myelin degeneration and necrosis preferentially affect the corpus callosum,
    producing the characteristic lesion of Marchiafava-Bignami disease.
  locations:
  - preferred_term: corpus callosum
    term:
      id: UBERON:0002336
      label: corpus callosum
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  cellular_components:
  - preferred_term: myelin sheath
    modifier: DECREASED
    term:
      id: GO:0043209
      label: myelin sheath
  evidence:
  - reference: PMID:37559750
    reference_title: "Diagnosis and Management of Marchiafava-Bignami Disease, a Rare Neurological Complication of Long-term Alcohol Abuse."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Marchiafava Bignami disease (MBD) is a neurological disorder characterized by myelin degeneration and tissue necrosis within the central nervous system.
    explanation: The review defines MBD by central nervous system myelin degeneration and necrosis.
  - reference: PMID:37559750
    reference_title: "Diagnosis and Management of Marchiafava-Bignami Disease, a Rare Neurological Complication of Long-term Alcohol Abuse."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most distinctive pathological feature of MBD is the necrotic degeneration specifically observed in the corpus callosum; however, emerging evidence also indicates the potential involvement of other brain regions.
    explanation: The quote identifies necrotic degeneration of the corpus callosum as the distinctive pathology.
  downstream:
  - target: Extracallosal white matter involvement
    description: More extensive toxic-metabolic injury can extend beyond the corpus callosum.
  - target: Interhemispheric disconnection syndrome
    description: Callosal fiber injury can produce interhemispheric disconnection signs.
- name: Extracallosal white matter involvement
  description: >-
    Lesions may extend outside the corpus callosum into adjacent or distant
    central nervous system white matter, and a broader lesion burden is a poor
    prognostic sign.
  locations:
  - preferred_term: central nervous system white matter
    term:
      id: UBERON:0016549
      label: central nervous system white matter layer
  cellular_components:
  - preferred_term: myelin sheath
    modifier: DECREASED
    term:
      id: GO:0043209
      label: myelin sheath
  evidence:
  - reference: PMID:39402444
    reference_title: Clinical analysis of Marchiafava-Bignami disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Lesions might also involve white matter outside the corpus callosum, and a wider range of lesions suggested a poor prognosis.
    explanation: The 33-case clinical analysis supports extracallosal lesion involvement and its prognostic implication.
- name: Interhemispheric disconnection syndrome
  description: >-
    Injury to corpus callosum fibers can impair interhemispheric transfer and
    contribute to disconnection signs, language disturbance, cognition changes,
    and motor manifestations.
  locations:
  - preferred_term: corpus callosum
    term:
      id: UBERON:0002336
      label: corpus callosum
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:33303506
    reference_title: Rare case of Marchiafava-Bignami disease due to thiamine deficiency and malnutrition.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The clinical presentation is varied and non-specific, including symptoms of acute dementia, impaired consciousness, dysarthria, hemiparesis, pyramidal tract signs, seizure activity, ataxia and signs of interhemispheric disconnection.
    explanation: The case-report abstract lists interhemispheric disconnection signs among MBD manifestations.
phenotypes:
- name: Reduced consciousness
  category: Neurologic
  description: Consciousness disturbance can range from confusion to coma or unconsciousness.
  phenotype_term:
    preferred_term: Reduced consciousness
    term:
      id: HP:0004372
      label: Reduced consciousness
  evidence:
  - reference: PMID:39402444
    reference_title: Clinical analysis of Marchiafava-Bignami disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Based on our analysis, we found that MBD primarily affects middle-aged men and typically has an acute or subacute onset, with the primary clinical manifestations being disturbances of consciousness, speech disorders, cognitive impairment, and psychiatric or behavioral abnormalities, often leading to misdiagnosis of psychiatric disorders.
    explanation: The case synthesis identifies disturbances of consciousness as a primary clinical manifestation.
  - reference: PMID:39791092
    reference_title: "An Atypical Case of Marchiafava-Bignami Disease in a Young Chronic Alcoholic: Challenges in Diagnosis and Prognosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A 27-year-old male patient with chronic alcohol use disorder was diagnosed with Marchiafava-Bignami disease (MBD) after experiencing an episode of unconsciousness.
    explanation: The case report documents unconsciousness at presentation.
- name: Speech disorder
  category: Neurologic
  description: Speech involvement includes dysarthria, aphasia, or impaired speech.
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: PMID:39402444
    reference_title: Clinical analysis of Marchiafava-Bignami disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Based on our analysis, we found that MBD primarily affects middle-aged men and typically has an acute or subacute onset, with the primary clinical manifestations being disturbances of consciousness, speech disorders, cognitive impairment, and psychiatric or behavioral abnormalities, often leading to misdiagnosis of psychiatric disorders.
    explanation: The case synthesis identifies speech disorders as a primary clinical manifestation.
  - reference: PMID:33303506
    reference_title: Rare case of Marchiafava-Bignami disease due to thiamine deficiency and malnutrition.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The clinical presentation is varied and non-specific, including symptoms of acute dementia, impaired consciousness, dysarthria, hemiparesis, pyramidal tract signs, seizure activity, ataxia and signs of interhemispheric disconnection.
    explanation: The case-report abstract specifically lists dysarthria.
- name: Aphasia
  category: Neurologic
  phenotype_term:
    preferred_term: Aphasia
    term:
      id: HP:0002381
      label: Aphasia
  evidence:
  - reference: PMID:39650996
    reference_title: "Marchiafava-Bignami Disease: A Case Report of a Reversible Cause of Dementia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report a case of MDB that was diagnosed in a 43-year-old woman with a history of chronic alcohol use and a 15-day history of progressive neurological symptoms, including impaired speech, confusion, and inability to walk independently.
    explanation: The abstract supports impaired speech, which may include aphasic or dysarthric presentations.
- name: Cognitive impairment
  category: Neuropsychiatric
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - reference: PMID:39402444
    reference_title: Clinical analysis of Marchiafava-Bignami disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Based on our analysis, we found that MBD primarily affects middle-aged men and typically has an acute or subacute onset, with the primary clinical manifestations being disturbances of consciousness, speech disorders, cognitive impairment, and psychiatric or behavioral abnormalities, often leading to misdiagnosis of psychiatric disorders.
    explanation: The case synthesis identifies cognitive impairment as a primary manifestation.
  - reference: PMID:39650996
    reference_title: "Marchiafava-Bignami Disease: A Case Report of a Reversible Cause of Dementia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The condition often presents with cognitive dysfunction, motor deficits, and altered consciousness, which can range from mild confusion to severe stupor.
    explanation: The case-report abstract describes cognitive dysfunction as a common presentation.
- name: Psychiatric or behavioral abnormality
  category: Neuropsychiatric
  phenotype_term:
    preferred_term: Psychiatric or behavioral abnormality
    term:
      id: HP:0000708
      label: Atypical behavior
  evidence:
  - reference: PMID:39402444
    reference_title: Clinical analysis of Marchiafava-Bignami disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Based on our analysis, we found that MBD primarily affects middle-aged men and typically has an acute or subacute onset, with the primary clinical manifestations being disturbances of consciousness, speech disorders, cognitive impairment, and psychiatric or behavioral abnormalities, often leading to misdiagnosis of psychiatric disorders.
    explanation: The case synthesis directly identifies psychiatric or behavioral abnormalities.
- name: Ataxia
  category: Neurologic
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:33303506
    reference_title: Rare case of Marchiafava-Bignami disease due to thiamine deficiency and malnutrition.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The clinical presentation is varied and non-specific, including symptoms of acute dementia, impaired consciousness, dysarthria, hemiparesis, pyramidal tract signs, seizure activity, ataxia and signs of interhemispheric disconnection.
    explanation: The case-report abstract lists ataxia among MBD manifestations.
- name: Hemiparesis
  category: Neurologic
  phenotype_term:
    preferred_term: Hemiparesis
    term:
      id: HP:0001269
      label: Hemiparesis
  evidence:
  - reference: PMID:33303506
    reference_title: Rare case of Marchiafava-Bignami disease due to thiamine deficiency and malnutrition.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The clinical presentation is varied and non-specific, including symptoms of acute dementia, impaired consciousness, dysarthria, hemiparesis, pyramidal tract signs, seizure activity, ataxia and signs of interhemispheric disconnection.
    explanation: The case-report abstract lists hemiparesis among MBD manifestations.
- name: Seizure
  category: Neurologic
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:33303506
    reference_title: Rare case of Marchiafava-Bignami disease due to thiamine deficiency and malnutrition.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The clinical presentation is varied and non-specific, including symptoms of acute dementia, impaired consciousness, dysarthria, hemiparesis, pyramidal tract signs, seizure activity, ataxia and signs of interhemispheric disconnection.
    explanation: The case-report abstract lists seizure activity among MBD manifestations.
- name: Apraxia
  category: Neurologic
  phenotype_term:
    preferred_term: Apraxia
    term:
      id: HP:0002186
      label: Apraxia
  evidence:
  - reference: DOI:10.1186/s12883-024-03901-y
    reference_title: Clinical analysis of Marchiafava-Bignami disease
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other clinical manifestations included emotional or personality changes (10 cases, 30.3%), seizures (4 cases, 12.1%), sensory disturbances (3 cases), neglect (2 cases), corpus callosum disconnection (2 cases), apraxia (4 cases), and combined neglect and apraxia (1 case).
    explanation: The 33-case synthesis reports apraxia in 4 cases and combined neglect/apraxia in 1 additional case.
  - reference: PMID:34473675
    reference_title: Disconnected Motor Intention and Spatial Attention in a Case of Probable Marchiafava-Bignami Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we report a man with probable MBD with callosal and right medial paracentral lesions who presented with abnormal reaching behavior and ideomotor apraxia of the left hand.
    explanation: The case-report abstract directly documents ideomotor apraxia in probable MBD.
environmental:
- name: Chronic alcohol use and malnutrition
  description: >-
    Chronic alcohol exposure and malnutrition are the major recurring clinical
    contexts for Marchiafava-Bignami disease.
  effect: Predisposes to thiamine depletion and toxic-metabolic callosal myelin injury.
  evidence:
  - reference: PMID:39402444
    reference_title: Clinical analysis of Marchiafava-Bignami disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Most patients have a history of alcohol consumption or malnutrition.
    explanation: The 33-case analysis identifies alcohol consumption and malnutrition as common histories.
  - reference: PMID:37559750
    reference_title: "Diagnosis and Management of Marchiafava-Bignami Disease, a Rare Neurological Complication of Long-term Alcohol Abuse."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This condition predominantly afflicts individuals with chronic alcohol abuse and malnutrition.
    explanation: The review identifies chronic alcohol abuse and malnutrition as the dominant clinical context.
diagnosis:
- name: Brain MRI with diffusion-weighted imaging
  description: >-
    MRI, especially diffusion-weighted imaging, is used to detect corpus callosum
    lesions and support early diagnosis.
  results: >-
    T2/FLAIR hyperintensity, diffusion-restricted corpus callosum lesions, or a
    central callosal signal abnormality with peripheral rim sparing
    ("sandwich sign") support the diagnosis.
  evidence:
  - reference: PMID:37559750
    reference_title: "Diagnosis and Management of Marchiafava-Bignami Disease, a Rare Neurological Complication of Long-term Alcohol Abuse."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      MRI is considered the gold standard for visualizing lesions in the corpus callosum and other affected areas.
    explanation: The review identifies MRI as the gold-standard imaging modality for MBD lesions.
  - reference: PMID:37559750
    reference_title: "Diagnosis and Management of Marchiafava-Bignami Disease, a Rare Neurological Complication of Long-term Alcohol Abuse."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      MRI-diffusion-weighted imaging (DWI) detects early lesions, while diffusion tensor imaging (DTI) investigates clinical manifestations and recovery.
    explanation: The review supports DWI for early lesion detection.
  - reference: PMID:33303506
    reference_title: Rare case of Marchiafava-Bignami disease due to thiamine deficiency and malnutrition.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis of MBD is dependent on MRI findings of hyperintensity of the corpus callosum on T2 and fluid-attenuated inversion recovery T2 sequences, with or without extracallosal lesions.
    explanation: The case-report abstract describes the MRI signal pattern used for diagnosis.
  - reference: DOI:10.15744/2454-4981.3.201
    reference_title: The Importance of Brain MRI in the Diagnosis of Marchiafava-Bignami Disease
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      FLAIR images may show central hypointense signal and peripheral hyperintense rim (“Sandwich sign”) [8].
    explanation: The imaging review documents the sandwich-sign pattern as a disease-supporting MRI feature.
treatments:
- name: Parenteral thiamine and B-vitamin repletion
  description: >-
    Prompt high-dose thiamine and B-vitamin replacement is the primary
    disease-directed treatment because thiamine depletion is a central
    mechanism and delayed therapy worsens outcomes.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: vitamin B1
      term:
        id: CHEBI:26948
        label: vitamin B1
  target_mechanisms:
  - target: Alcohol-related thiamine depletion
    description: Thiamine replacement addresses the deficiency-associated upstream driver.
  - target: Impaired myelin synthesis and signal transmission
    description: Vitamin repletion is intended to support restoration of myelin metabolism.
  evidence:
  - reference: PMID:37559750
    reference_title: "Diagnosis and Management of Marchiafava-Bignami Disease, a Rare Neurological Complication of Long-term Alcohol Abuse."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Notably, thiamine treatment reduces the likelihood of unfavorable consequences, particularly when administered promptly, and thus is endorsed as the primary therapeutic approach for MBD.
    explanation: The review supports prompt thiamine as the primary therapeutic approach.
  - reference: PMID:39650996
    reference_title: "Marchiafava-Bignami Disease: A Case Report of a Reversible Cause of Dementia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The patient was treated with high-dose intravenous thiamine and B vitamins, resulting in a gradual and significant improvement.
    explanation: The case report directly supports clinical improvement after high-dose intravenous thiamine and B vitamins.
  - reference: PMID:33303506
    reference_title: Rare case of Marchiafava-Bignami disease due to thiamine deficiency and malnutrition.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Administration of thiamine within 14 days of symptom onset has demonstrated statistically better outcomes over delayed treatment.
    explanation: The case-report abstract supports early thiamine treatment.
- name: Adjunct corticosteroid therapy
  description: >-
    Corticosteroids are sometimes used as adjunctive therapy for edema,
    demyelination, and inflammation, but evidence is heterogeneous and often
    confounded by concurrent vitamin treatment.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: corticosteroid
      term:
        id: CHEBI:50858
        label: corticosteroid
  target_mechanisms:
  - target: Callosal myelin degeneration and necrosis
    description: Corticosteroids are used to address edema, demyelination, and inflammation around lesions.
  - target: Cytotoxic edema in callosal white matter
    description: Corticosteroids are used as adjunctive therapy for edema around acute lesions.
  evidence:
  - reference: PMID:37559750
    reference_title: "Diagnosis and Management of Marchiafava-Bignami Disease, a Rare Neurological Complication of Long-term Alcohol Abuse."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Corticosteroids offer prospective advantages in addressing brain edema, demyelination, and inflammation; research findings present a heterogeneous outcome pattern.
    explanation: The review supports a plausible adjunctive role but explicitly notes heterogeneous outcomes.
  - reference: PMID:39791092
    reference_title: "An Atypical Case of Marchiafava-Bignami Disease in a Young Chronic Alcoholic: Challenges in Diagnosis and Prognosis."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Despite prompt initiation of intensive treatment with high-dose thiamine and corticosteroids, the patient only partially recovered, remaining disoriented and exhibiting persistent neurological deficits during follow-up.
    explanation: This case documents corticosteroid use with only partial recovery, supporting a cautious PARTIAL classification.
- name: Rehabilitation therapy and multidisciplinary supportive care
  description: >-
    Rehabilitation and multidisciplinary supportive care may be used alongside
    vitamin repletion and pharmacotherapy to address gait, speech, and functional
    deficits during recovery.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  target_mechanisms:
  - target: Interhemispheric disconnection syndrome
    description: Rehabilitation addresses downstream functional deficits from callosal injury.
  evidence:
  - reference: DOI:10.51338/rppsm.2020.v6.i1.120
    reference_title: "Marchiafava-Bignami Disease: The Importance of Early Diagnosis and Treatment by a Multidisciplinary Team"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      He received thiamine, corticosteroids and rehabilitation.
    explanation: The case-report abstract documents rehabilitation as part of multidisciplinary treatment.
clinical_trials: []
datasets:
📚

References & Deep Research

References

8
DOI:10.15190/d.2023.7
Diagnosis and Management of Marchiafava-Bignami Disease, a Rare Neurological Complication of Long-term Alcohol Abuse
No top-level findings curated for this source.
DOI:10.1186/s12883-024-03901-y
Clinical analysis of Marchiafava-Bignami disease
No top-level findings curated for this source.
DOI:10.7759/cureus.73146
Marchiafava-Bignami Disease: A Case Report of a Reversible Cause of Dementia
No top-level findings curated for this source.
DOI:10.1038/s41598-023-45431-6
Clinico-radiologic subtypes and therapeutic observation of acute Marchiafava-Bignami disease
No top-level findings curated for this source.
DOI:10.1177/0284185120943040
Diverse MRI findings and clinical outcomes of acute Marchiafava-Bignami disease
No top-level findings curated for this source.
DOI:10.1136/bcr-2020-238187
Rare case of Marchiafava-Bignami disease due to thiamine deficiency and malnutrition
No top-level findings curated for this source.
DOI:10.7759/cureus.75468
An Atypical Case of Marchiafava-Bignami Disease in a Young Chronic Alcoholic: Challenges in Diagnosis and Prognosis
No top-level findings curated for this source.
DOI:10.15744/2454-4981.3.201
The Importance of Brain MRI in the Diagnosis of Marchiafava-Bignami Disease
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 29 citations 2026-05-06T13:44:14.690996

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Marchiafava-Bignami Disease
  • MONDO ID: (if available)
  • Category: Neurological Disorder

Research Objectives

Please provide a comprehensive research report on Marchiafava-Bignami Disease covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Disease Characteristics Report: Marchiafava–Bignami Disease (MBD)

Target Disease

  • Disease name: Marchiafava–Bignami disease (MBD)
  • Category: Neurological disorder (toxic-metabolic demyelinating/necrotizing disease of the corpus callosum) (singer2023diagnosisandmanagement pages 1-2, liu2024clinicalanalysisof pages 1-2)

1) Disease Information

1.1 Overview (current understanding)

Marchiafava–Bignami disease (MBD) is a rare neurologic disorder characterized by demyelination and necrosis of the corpus callosum, sometimes extending into adjacent subcortical/extra-callosal white matter. It is most strongly associated with chronic alcohol use disorder and malnutrition, and often presents with nonspecific neuropsychiatric symptoms that can delay diagnosis. MRI (particularly DWI) enables antemortem diagnosis and earlier treatment. (singer2023diagnosisandmanagement pages 1-2, liu2024clinicalanalysisof pages 1-2, singer2023diagnosisandmanagement pages 4-6)

Example abstract-supported definition (direct quote): the 2023 review describes MBD as “characterized by… myelin degeneration and tissue necrosis… [with]… necrotic degeneration… in the corpus callosum.” (published 2023-06-30; URL: https://doi.org/10.15190/d.2023.7) (singer2023diagnosisandmanagement pages 1-2)

1.2 Key identifiers (OMIM/Orphanet/ICD/MeSH/MONDO)

Authoritative ontology identifiers (e.g., Orphanet, ICD-10/ICD-11, MeSH, MONDO) were not retrievable from the sources available in this tool run, so they cannot be confirmed here.

1.3 Synonyms and alternative names

  • Marchiafava–Bignami disease (MBD) (singer2023diagnosisandmanagement pages 1-2, liu2024clinicalanalysisof pages 1-2)
  • Primary degeneration of the corpus callosum (used in imaging-oriented literature) (li2021diversemrifindings pages 1-3)

1.4 Evidence type (patient-level vs aggregated)

Most MBD knowledge is derived from case reports/series and small retrospective cohorts, rather than randomized clinical trials. A 2024 paper synthesized 33 cases (3 institutional cases plus 30 published case reports) to summarize clinical characteristics. (published 2024-10; URL: https://doi.org/10.1186/s12883-024-03901-y) (liu2024clinicalanalysisof pages 1-2)

2) Etiology

2.1 Disease causal factors (current view)

The leading causal model is toxic–metabolic injury related to alcohol exposure and nutritional deficiency, particularly thiamine (vitamin B1) depletion, producing energy failure, cytotoxic edema, demyelination, and necrosis in myelin-rich callosal tissue. (singer2023diagnosisandmanagement pages 1-2, menrai2024anatypicalcase pages 1-2)

Direct quote (abstract): alcohol “leads to thiamine depletion and disrupts various metabolic pathways… [which] hinders myelin synthesis.” (Singer et al., 2023-06-30; https://doi.org/10.15190/d.2023.7) (singer2023diagnosisandmanagement pages 1-2)

2.2 Risk factors

Major risk factors include: - Chronic alcohol use disorder and malnutrition (liu2024clinicalanalysisof pages 1-2, singer2023diagnosisandmanagement pages 1-2) - Thiamine/B-complex vitamin deficiency (singer2023diagnosisandmanagement pages 1-2)

Non-alcoholic triggers/associations reported in reviews include diabetic ketoacidosis and osmolality shifts (“callosal myelinolysis”), post-bariatric malnutrition, sepsis, carbon monoxide poisoning, cerebral malaria, and sickle cell disease. (singer2023diagnosisandmanagement pages 2-4)

Recent aggregated data (2017–2023 case reports): “Most patients have a history of alcohol consumption or malnutrition.” (Liu et al., 2024-10; https://doi.org/10.1186/s12883-024-03901-y) (liu2024clinicalanalysisof pages 1-2)

2.3 Protective factors

No genetic or pharmacologic protective factors were identified in the retrieved evidence. Indirectly, adequate nutrition and alcohol abstinence are protective in the sense of removing major risk exposures. (singer2023diagnosisandmanagement pages 1-2)

2.4 Gene–environment interaction

No specific gene–environment interactions are established in the retrieved literature; one case report states the cause “may involve… genetic predisposition” but does not provide gene/variant evidence. (Conceição et al., 2024-11-06; https://doi.org/10.7759/cureus.73146) (conceicao2024marchiafavabignamidiseasea pages 1-3)

3) Phenotypes

3.1 Core phenotypes and frequency (human clinical evidence)

A 2024 retrospective synthesis of 33 cases (2017–2023 case reports plus 3 institutional cases) quantified phenotype frequencies as follows (published 2024-10; https://doi.org/10.1186/s12883-024-03901-y): (liu2024clinicalanalysisof pages 2-4) - Movement disorder/dyskinesia: 22/33 (66.7%) (e.g., ataxia, limb weakness) (liu2024clinicalanalysisof pages 2-4) - Speech disorders: 19/33 (57.6%) (e.g., dysarthria, aphasia) (liu2024clinicalanalysisof pages 2-4) - Consciousness disorders: 18/33 (54.5%) (e.g., coma, somnolence, agitation) (liu2024clinicalanalysisof pages 2-4) - Cognitive impairment: 15/33 (45.5%) (liu2024clinicalanalysisof pages 2-4) - Emotional/personality change: 10/33 (30.3%) (liu2024clinicalanalysisof pages 2-4) - Seizures: 4/33 (12.1%) (liu2024clinicalanalysisof pages 2-4)

3.2 Onset age, severity, progression

  • Typical age/sex: primarily affects middle-aged men in aggregated data (liu2024clinicalanalysisof pages 1-2)
  • Onset pattern: often acute or subacute (liu2024clinicalanalysisof pages 1-2)
  • Temporal staging: acute/subacute/chronic presentations are described in recent clinical literature; acute cases can include confusion/aggression/seizures, with chronic cases including progressive dementia-like syndromes. (conceicao2024marchiafavabignamidiseasea pages 3-4)

Quantitative course distribution (33 cases): acute 18/33 (54.5%), subacute 7/33 (21.2%), chronic 8/33 (24.2%). (liu2024clinicalanalysisof pages 2-4)

3.3 Suggested HPO terms (examples)

(These are ontology suggestions; exact mappings should be verified against HPO.) - Altered level of consciousness (e.g., coma/somnolence): HP:0001259 (common umbrella; exact term selection depends on case detail) (liu2024clinicalanalysisof pages 2-4) - Ataxia: HP:0001251 (liu2024clinicalanalysisof pages 2-4) - Dysarthria: HP:0001260 (liu2024clinicalanalysisof pages 2-4) - Aphasia: HP:0002381 (liu2024clinicalanalysisof pages 2-4) - Cognitive impairment: HP:0100543 (liu2024clinicalanalysisof pages 2-4) - Seizures: HP:0001250 (liu2024clinicalanalysisof pages 2-4) - Apraxia: HP:0002186 (liu2024clinicalanalysisof pages 2-4) - Neuropsychiatric/behavioral abnormality (broad): consider HP:0000708 (behavior abnormality) and/or more specific terms based on presentation (liu2024clinicalanalysisof pages 2-4)

3.4 Quality of life impact

Formal QoL instruments (EQ-5D/SF-36) were not identified in the retrieved literature. However, severe cases can lead to prolonged dependency and persistent deficits (e.g., neurogenic bladder, disorientation), indicating substantial functional impact. (menrai2024anatypicalcase pages 1-2)

4) Genetic / Molecular Information

4.1 Causal genes and pathogenic variants

MBD is not established as a monogenic disease in the retrieved evidence, and no causal genes/variants or ClinVar-style variant assertions were identified.

4.2 Mechanistic molecular pathways (non-genetic)

Mechanistic framing emphasizes metabolic and oxidative injury in callosal white matter, including: - Thiamine depletion → impaired energy metabolism → cytotoxic edema (reflected by restricted diffusion/low ADC) → demyelination/necrosis (singer2023diagnosisandmanagement pages 4-6, singer2023diagnosisandmanagement pages 1-2)

Suggested GO biological process terms (examples; to validate in GO): - Myelination (GO:0042552) - Axon ensheathment (GO:0008366) - Response to oxidative stress (GO:0006979) - Regulation of inflammatory response (GO:0050727)

5) Environmental Information

5.1 Environmental/lifestyle factors

The dominant environmental/lifestyle drivers are: - Chronic heavy alcohol exposure (liu2024clinicalanalysisof pages 1-2, zhang2023clinicoradiologicsubtypesand pages 1-2) - Malnutrition / inadequate intake and associated vitamin deficiency (liu2024clinicalanalysisof pages 1-2)

A 2023 cohort described long drinking histories (12–29 years; ~200–250 mL/day of 40–50% liquor). (Zhang et al., 2023-10; https://doi.org/10.1038/s41598-023-45431-6) (zhang2023clinicoradiologicsubtypesand pages 1-2)

5.2 Infectious agents

Not a primary infectious disease; however, cerebral malaria is listed as a reported association/trigger in review literature. (singer2023diagnosisandmanagement pages 2-4)

6) Mechanism / Pathophysiology

6.1 Causal chain (integrated)

A clinically useful causal chain consistent with recent reviews and cohort imaging is: 1) Chronic alcohol use and/or malnutrition → thiamine depletion and metabolic disruption (singer2023diagnosisandmanagement pages 1-2) 2) Energy failure in myelin-rich callosal tracts → cytotoxic edema (restricted diffusion/low ADC on DWI) (singer2023diagnosisandmanagement pages 4-6, zhang2023clinicoradiologicsubtypesand pages 1-2) 3) Demyelination and necrosis within corpus callosum ± extracallosal white matter (singer2023diagnosisandmanagement pages 1-2, liu2024clinicalanalysisof pages 1-2) 4) Clinical syndrome: altered consciousness, dysarthria/aphasia, ataxia/weakness, cognitive and psychiatric changes, disconnection syndromes (liu2024clinicalanalysisof pages 2-4, singer2023diagnosisandmanagement pages 7-9)

6.2 Cell types (suggested CL terms)

Specific single-cell evidence was not found. Relevant cell types likely include: - Oligodendrocyte (CL:0000128) - Astrocyte (CL:0000127) - Microglial cell (CL:0000129)

This is consistent with demyelinating pathology described in review literature (e.g., demyelination, decreased oligodendrocytes). (singer2023diagnosisandmanagement pages 4-6)

7) Anatomical Structures Affected

7.1 Organ/tissue localization

  • Primary: corpus callosum (white matter commissure) (liu2024clinicalanalysisof pages 1-2, singer2023diagnosisandmanagement pages 1-2)
  • Common subregions: splenium is frequently affected in case syntheses; anterior two-thirds and other callosal segments can be involved (liu2024clinicalanalysisof pages 1-2, conceicao2024marchiafavabignamidiseasea pages 1-3)
  • Secondary/extra-callosal involvement: hemispheric white matter and other brain regions can be involved; extracallosal involvement correlates with severity and can be a poor prognostic feature. (singer2023diagnosisandmanagement pages 1-2, liu2024clinicalanalysisof pages 1-2, zhang2023clinicoradiologicsubtypesand pages 1-2)

Suggested UBERON terms (examples; verify in Uberon): - Corpus callosum: UBERON:0001877 - Cerebral white matter: UBERON:0016549 (or alternative white-matter term depending on ontology version)

7.2 Imaging illustration (MRI)

A 2024 case report provides representative MRI findings: T2/FLAIR hyperintensity of the anterior two-thirds of the corpus callosum with restricted diffusion on DWI/ADC consistent with acute edema/demyelination. (Conceição et al., 2024-11-06; https://doi.org/10.7759/cureus.73146) (conceicao2024marchiafavabignamidiseasea media 16521e3e, conceicao2024marchiafavabignamidiseasea media 7c11b093, conceicao2024marchiafavabignamidiseasea media 8bf57d9d)

8) Temporal Development

8.1 Onset

Commonly acute or subacute, though chronic forms occur. (liu2024clinicalanalysisof pages 1-2)

8.2 Progression and staging

Clinical literature commonly describes acute/subacute/chronic courses; the 2024 case report summarizes stage-associated symptom patterns (acute confusion/seizures; subacute dysarthria/apraxia/ataxia; chronic global dementia/behavioral changes). (conceicao2024marchiafavabignamidiseasea pages 3-4)

9) Inheritance and Population

9.1 Inheritance

No Mendelian inheritance pattern is established; disease is best characterized as acquired/toxic-metabolic in the retrieved evidence.

9.2 Epidemiology

Population prevalence/incidence estimates were not identified in the retrieved sources. The 2023 review notes rarity and describes a historical compilation of ~250 cases before 2001. (singer2023diagnosisandmanagement pages 2-4)

10) Diagnostics

10.1 Imaging

  • MRI is the diagnostic gold standard for demonstrating callosal lesions in MBD. (singer2023diagnosisandmanagement pages 1-2, conceicao2024marchiafavabignamidiseasea pages 3-4)
  • DWI is emphasized for early lesion detection and shows restricted diffusion with low ADC, supporting acute cytotoxic edema. (singer2023diagnosisandmanagement pages 4-6, zhang2023clinicoradiologicsubtypesand pages 1-2)
  • The “sandwich sign” (central callosal lesion with sparing of dorsal and ventral layers) is described as a hallmark imaging pattern in acute disease. (menrai2024anatypicalcase pages 2-3, cm2017theimportanceof pages 1-3)

10.2 Laboratory testing / biomarkers

No validated disease-specific biomarker panel is established; labs often reflect nutritional and alcohol-related abnormalities and are used to evaluate deficiencies and exclude mimics. A 2024 case report found macrocytic anemia, folate deficiency, mild hypoalbuminemia, and elevated GGT. (conceicao2024marchiafavabignamidiseasea pages 1-3)

10.3 Differential diagnosis

A 2023 review provides a broad differential including Wernicke encephalopathy, vitamin B12/folate deficiency, metabolic/toxic etiologies, central myelinolysis, MS, infection/encephalitis, tumors, and systemic organ failure syndromes. (Singer et al., 2023-06-30; https://doi.org/10.15190/d.2023.7) (singer2023diagnosisandmanagement pages 7-9)

11) Outcome / Prognosis

11.1 Prognostic factors

Poor outcome predictors emphasized in reviews and recent cases include: - Severe consciousness disturbance/low GCS (menrai2024anatypicalcase pages 1-2) - Extensive cerebral cortex or extracallosal involvement (singer2023diagnosisandmanagement pages 1-2, zhang2023clinicoradiologicsubtypesand pages 1-2) - Delayed treatment; earlier thiamine is associated with better outcomes in review literature (singer2023diagnosisandmanagement pages 7-9)

11.2 Quantitative outcome data from cohorts

  • In a 2023 acute cohort (n=23), Heinrich Type A vs B differed in admission MoCA and extracallosal involvement, but authors concluded prognosis could still be favorable with combined treatment and lesions could resolve. (Zhang et al., 2023-10; https://doi.org/10.1038/s41598-023-45431-6) (zhang2023clinicoradiologicsubtypesand pages 1-2)
  • In a 17-patient acute MRI cohort, neuropsychiatric sequelae were reported in 5 cases overall, with higher sequelae in the most focal diffusion subtype (Type III: 60%). (Li et al., accepted 2020-06-16, published 2021-07; https://doi.org/10.1177/0284185120943040) (li2021diversemrifindings pages 1-3)

11.3 Mortality statistic (from review literature)

A 2020 BMJ Case Reports review reports that MRI-enabled diagnosis and earlier thiamine treatment improved prognosis “from frequently fatal to a mortality of less than 8%,” and that thiamine administered within 14 days is associated with statistically better outcomes. (Kinsley et al., 2020-12; https://doi.org/10.1136/bcr-2020-238187) (singer2023diagnosisandmanagement pages 1-2)

12) Treatment

12.1 Core pharmacotherapy (real-world implementation)

There are no universally accepted treatment guidelines, but convergent expert consensus and practice patterns support: - Immediate high-dose parenteral thiamine and B-complex vitamin replacement as first-line therapy (singer2023diagnosisandmanagement pages 1-2, conceicao2024marchiafavabignamidiseasea pages 3-4) - Nutritional rehabilitation and alcohol cessation/withdrawal management (zhang2023clinicoradiologicsubtypesand pages 1-2) - Rehabilitation therapies (physical/occupational/speech as indicated) (menrai2024anatypicalcase pages 1-2)

Example thiamine dosing used in a 2023 cohort: IV thiamine 500 mg/day plus methylprednisolone pulse 500–1000 mg/day for 3–5 days, then oral prednisone and compound B vitamins, with follow-up oral B vitamins and alcohol withdrawal. (Zhang et al., 2023-10; https://doi.org/10.1038/s41598-023-45431-6) (zhang2023clinicoradiologicsubtypesand pages 1-2)

Example dosing in a 2024 case report: IV thiamine 500 mg three times daily for 3 days, then 250 mg IV daily for 5 days, then 100 mg orally daily, plus B6/B9/B12 and rehabilitation. (Conceição et al., 2024-11-06; https://doi.org/10.7759/cureus.73146) (conceicao2024marchiafavabignamidiseasea pages 3-4)

12.2 Corticosteroids (evidence status)

Corticosteroids are frequently co-administered to address edema/inflammation, but reviews emphasize heterogeneous evidence and confounding by simultaneous vitamin therapy; thiamine remains the most consistently recommended intervention. (singer2023diagnosisandmanagement pages 7-9, singer2023diagnosisandmanagement pages 4-6)

12.3 Suggested MAXO terms (examples)

(Verify exact MAXO identifiers in MAXO.) - Thiamine supplementation / vitamin B supplementation (zhang2023clinicoradiologicsubtypesand pages 1-2, conceicao2024marchiafavabignamidiseasea pages 3-4) - Corticosteroid therapy (zhang2023clinicoradiologicsubtypesand pages 1-2) - Nutritional rehabilitation (liu2024clinicalanalysisof pages 1-2) - Alcohol cessation counseling / substance use treatment (zhang2023clinicoradiologicsubtypesand pages 1-2) - Rehabilitation therapy (menrai2024anatypicalcase pages 1-2)

13) Prevention

Primary prevention is largely exposure-based: - Prevent chronic malnutrition and vitamin deficiency in high-risk populations (alcohol use disorder, poor intake, post-surgical malabsorption) (liu2024clinicalanalysisof pages 1-2) - Early empiric thiamine in suspected deficiency states (modelled after Wernicke-Korsakoff practice patterns in reviews) (singer2023diagnosisandmanagement pages 4-6)

Secondary prevention is essentially early recognition (MRI use in appropriate presentations) to prevent irreversible injury. (singer2023diagnosisandmanagement pages 1-2)

14) Other Species / Natural Disease

No naturally occurring MBD analogs in non-human species were identified in the retrieved evidence.

15) Model Organisms

No validated disease-specific animal models were identified in the retrieved evidence. Mechanistic hypotheses largely extrapolate from thiamine deficiency and alcohol neurotoxicity biology rather than MBD-specific models.

Recent Developments (2023–2024 highlight)

1) Clinico-radiologic subtyping with treatment response: a 2023 cohort (n=23) validated Heinrich Type A/B comparisons and reported complete clinico-radiologic recovery with combined therapy, emphasizing reversibility. (Zhang et al., 2023-10; https://doi.org/10.1038/s41598-023-45431-6) (zhang2023clinicoradiologicsubtypesand pages 1-2) 2) Updated aggregated phenotype frequencies and onset distributions: a 2024 synthesis of 33 cases quantified symptom frequencies and reinforced extracallosal lesion burden as a poor prognostic marker. (Liu et al., 2024-10; https://doi.org/10.1186/s12883-024-03901-y) (liu2024clinicalanalysisof pages 2-4)

Current Applications / Real-World Implementations

  • Emergency and inpatient neurology: MRI (especially DWI) to distinguish MBD from stroke and other toxic-metabolic encephalopathies, followed by empiric high-dose thiamine and supportive care. (singer2023diagnosisandmanagement pages 1-2, conceicao2024marchiafavabignamidiseasea pages 1-3)
  • Monitoring and prognosis: DWI lesion extent and extracallosal involvement used as practical indicators of severity and potential outcome. (zhang2023clinicoradiologicsubtypesand pages 1-2, liu2024clinicalanalysisof pages 1-2)

Clinical Trials (translation status)

No MBD-specific therapeutic trials were identified. One interventional trial relevant to corpus callosum demyelination is: - NCT06065670 (ClinicalTrials.gov): “Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy” (UCSF). Status: Not yet recruiting; estimated start: 2026-09-15; Phase: 1/2; n≈44. The trial targets acute demyelinating lesions broadly (e.g., MS-related) with corpus callosum myelin MRI outcomes; MBD appears in condition taxonomy but the study is not clearly MBD-specific. URL (ClinicalTrials.gov): https://clinicaltrials.gov/study/NCT06065670 (NCT06065670 chunk 1, NCT06065670 chunk 4)

Summary Table (evidence-synthesized)

Domain Key facts Quantitative details / examples Evidence
Definition Rare neurologic disorder characterized by demyelination and necrosis of the corpus callosum, often with adjacent subcortical/extra-callosal white matter involvement; classically linked to chronic alcohol use and malnutrition. Older literature cited in recent reviews suggests only ~250 published cases before 2001; a 2024 review article notes ~300 cases worldwide. (singer2023diagnosisandmanagement pages 1-2, liu2024clinicalanalysisof pages 1-2, menrai2024anatypicalcase pages 1-2, conceicao2024marchiafavabignamidiseasea pages 1-3)
Disease context / data source Evidence is largely from aggregated disease-level reviews plus retrospective analyses of published case reports and small hospital cohorts, rather than EHR-scale datasets or randomized trials. 33-case retrospective synthesis (3 local + 30 published cases, 2017–2023); 23-patient acute MBD cohort; 17-patient MRI cohort. (liu2024clinicalanalysisof pages 1-2, zhang2023clinicoradiologicsubtypesand pages 1-2, li2021diversemrifindings pages 1-3)
Typical triggers / risk factors Chronic alcohol use disorder, malnutrition, thiamine/B-complex deficiency; also reported after GI surgery, anorexia, unbalanced diet, post-bariatric malnutrition, diabetic ketoacidosis/callosal myelinolysis, sepsis, carbon monoxide poisoning, cerebral malaria, and sickle cell disease. In a 23-patient acute cohort, drinking history was 12–29 years with ~200–250 mL/day of 40–50% liquor; in a 17-patient cohort, 12–45 years with ~250–500 mL/day. (liu2024clinicalanalysisof pages 1-2, singer2023diagnosisandmanagement pages 1-2, zhang2023clinicoradiologicsubtypesand pages 1-2, li2021diversemrifindings pages 1-3)
Pathophysiologic understanding Leading mechanisms include alcohol neurotoxicity, oxidative stress, thiamine depletion with energy failure, impaired myelin synthesis, cytotoxic edema, blood-brain-barrier dysfunction, demyelination, and necrosis. Extra-callosal involvement likely reflects more severe diffuse injury. Reviews emphasize low ADC/restricted diffusion as a marker of cytotoxic edema that may precede necrosis; poor outcome linked to widespread cortical/extra-callosal disease. (singer2023diagnosisandmanagement pages 1-2, singer2023diagnosisandmanagement pages 4-6, menrai2024anatypicalcase pages 1-2)
Onset / course Acute, subacute, or chronic presentations occur; acute/subacute onset is common in contemporary series. In the 33-case synthesis: acute 18/33 (54.5%), subacute 7/33 (21.2%), chronic 8/33 (24.2%). (liu2024clinicalanalysisof pages 2-4)
Core clinical phenotypes Disturbance of consciousness, dysarthria/aphasia, cognitive impairment, psychiatric/behavioral change, ataxia, weakness, seizures, apraxia/neglect, and interhemispheric disconnection syndrome. In 33 cases: dyskinesia 22/33 (66.7%), speech disorders 19/33 (57.6%), consciousness disorders 18/33 (54.5%), cognitive impairment 15/33 (45.5%), emotional/personality change 10/33 (30.3%), seizures 4/33 (12.1%), sensory disturbance 3/33, neglect 2/33, apraxia 4/33, callosal disconnection 2/33. Among acute-onset cases: consciousness disorders 14/18 (77.8%), speech disorders 12/18 (66.7%), movement disorders 11/18 (61.1%). (liu2024clinicalanalysisof pages 1-2, liu2024clinicalanalysisof pages 2-4)
Common lesion locations Symmetric corpus callosum lesions are typical; splenium is often most commonly affected in mixed case series, but genu/body and anterior two-thirds involvement also occur; lesions may extend to hemispheric white matter, internal capsule, basal ganglia, and other extra-callosal regions. 2024 synthesis: splenium most commonly affected; broader lesion distribution associated with worse prognosis. Case imaging examples show anterior 2/3 callosal involvement with mild splenial involvement and DWI restriction. (liu2024clinicalanalysisof pages 1-2, conceicao2024marchiafavabignamidiseasea pages 1-3, li2021diversemrifindings pages 1-3, singer2023diagnosisandmanagement pages 1-2)
Key MRI findings MRI is the diagnostic gold standard. Typical findings are T1 hypointensity and T2/FLAIR hyperintensity in callosal lesions; DWI detects early lesions and shows restricted diffusion with low ADC in acute disease. Restricted diffusion defined as DWI hyperintensity with ADC hypointensity; examples documented in anterior 2/3 of corpus callosum and splenium. (singer2023diagnosisandmanagement pages 1-2, zhang2023clinicoradiologicsubtypesand pages 1-2, conceicao2024marchiafavabignamidiseasea pages 1-3, li2021diversemrifindings pages 1-3)
Signature imaging sign “Sandwich sign”: central callosal lesion with sparing of dorsal and ventral layers, especially described in acute disease and often highlighted on sagittal imaging. Recent and prior reviews describe it as a hallmark/pathognomonic sign of acute MBD. (menrai2024anatypicalcase pages 2-3, cm2017theimportanceof pages 1-3, li2021diversemrifindings pages 1-3)
Imaging-based evolution Acute lesions may show swelling and extensive diffusion restriction; follow-up can show radiologic resolution, but some cases evolve to callosal atrophy or cavitation, especially with more focal/heterogeneous callosal injury. In the 17-patient MRI cohort, callosal atrophy/cavitation occurred in 0% of Type I, 20% of Type II, and 60% of Type III cases. (li2021diversemrifindings pages 1-3)
Heinrich clinicoradiologic subtype A/B Type A: diffuse/entire callosal involvement with more severe early presentation; Type B: focal callosal involvement with milder presentation. In the 23-patient cohort: Type A n=12, Type B n=11; admission MoCA 16.50±1.73 vs 18.27±1.68 (P=0.021); extracallosal involvement 66.67% vs 18.18% (P=0.036); illness duration 18.3±2.1 vs 15.6±2.4 days (P=0.012); residual splenial lesion during treatment 58.33% vs 9.09% (P=0.027). Authors concluded subtype related to early severity, not final prognosis, with recovery possible in both. (zhang2023clinicoradiologicsubtypesand pages 1-2)
MRI diffusion-range subtype I/II/III Type I = complete callosal restricted diffusion; Type II = mostly involved; Type III = partial involvement. Greater diffusion extent was associated with more extracallosal lesions but fewer chronic sequelae, while more focal/heterogeneous lesions had more atrophy/cavitation and sequelae. Extracallosal involvement: Type I 6/7 (86%), Type II 3/5 (60%), Type III 1/5 (20%). Neuropsychiatric sequelae at follow-up: Type I 1/7 (14%), Type II 1/5 (20%), Type III 3/5 (60%). (li2021diversemrifindings pages 1-3)
Laboratory / ancillary findings Routine labs may be normal or show nutritional/alcohol-related abnormalities; testing helps exclude mimics. Reported abnormalities include macrocytic anemia, folate deficiency, hypoalbuminemia, liver enzyme elevation. Example case: Hb 10.7 g/dL, MCV 110.1 fL, folate <0.6 ng/mL, GGT 131 U/L, albumin 3.35 g/dL. (conceicao2024marchiafavabignamidiseasea pages 1-3)
Differential diagnosis Wernicke encephalopathy, vitamin B12/folate deficiency syndromes, multiple sclerosis, central pontine/extrapontine myelinolysis, encephalitis/meningitis, seizures/epilepsy-related lesions, metabolic/toxic encephalopathies, tumors, dementia syndromes, hepatic/renal/respiratory failure, sepsis, delirium. Differentiation relies on alcoholism/malnutrition context, more persistent severe cognitive-motor syndrome, and characteristic callosal MRI lesions. (singer2023diagnosisandmanagement pages 7-9, singer2023diagnosisandmanagement pages 1-2)
First-line treatment Prompt parenteral thiamine/B-complex vitamin replacement is the mainstay; alcohol cessation, nutritional rehabilitation, and supportive multidisciplinary care are standard. Example regimens reported: thiamine 500 mg/day IV for 3–5 days with steroids, then oral B vitamins; alternative review regimen 100–250 mg IV/IM daily for 3–5 days, then 100 mg PO TID for 1–2 weeks, then 100 mg daily maintenance; case regimen 500 mg IV three times daily for 3 days, then 250 mg IV daily for 5 days, then 100 mg PO daily. (zhang2023clinicoradiologicsubtypesand pages 1-2, singer2023diagnosisandmanagement pages 4-6, conceicao2024marchiafavabignamidiseasea pages 3-4)
Corticosteroids / adjuncts Corticosteroids are used in many reports to address edema, demyelination, and inflammation, but evidence is heterogeneous and confounded by concurrent vitamin therapy. Rehabilitation and nutritional support are commonly added. Example steroid regimens: methylprednisolone 500–1000 mg/day for 3–5 days followed by oral prednisone 60 mg/day taper; dexamethasone 4 mg every 12 h in one severe case. (zhang2023clinicoradiologicsubtypesand pages 1-2, singer2023diagnosisandmanagement pages 1-2, menrai2024anatypicalcase pages 1-2)
Treatment response Improvement can be substantial and radiologically reversible when recognized early; however, partial recovery with chronic neuropsychiatric deficits also occurs. In the 23-patient cohort, MoCA improved over time in both subtypes (P<0.001) and callosal/extracallosal lesions disappeared completely. A 2024 case regained coherent speech and independent walking after 1 month of treatment; another severe 2024 case had minimal improvement at 1 year. (zhang2023clinicoradiologicsubtypesand pages 1-2, conceicao2024marchiafavabignamidiseasea pages 1-3, menrai2024anatypicalcase pages 1-2)
Prognostic factors Worse prognosis is associated with extensive extra-callosal/cortical involvement, severe consciousness disturbance or low GCS, broader lesion burden, and delayed treatment. Earlier thiamine appears beneficial. Review notes MBD co-occurs with Wernicke disease in ~15–20% of cases. Early thiamine reduced unfavorable outcomes; a BMJ review article cited mortality of <8% in the MRI era and better outcomes when thiamine was given within 14 days of symptom onset. (singer2023diagnosisandmanagement pages 1-2, singer2023diagnosisandmanagement pages 4-6, menrai2024anatypicalcase pages 1-2)
Real-world implementation / recent developments Current real-world practice is MRI-based diagnosis plus empiric high-dose thiamine, vitamins, alcohol withdrawal, and rehabilitation. Recent research includes retrospective clinico-radiologic subtype studies and exploratory AI/MRI detection work, but no disease-specific therapeutic trials were identified in the retrieved evidence. 2023–2024 literature emphasizes MRI/DWI-guided diagnosis, subtype-outcome correlation, and reversibility with combined therapy. (zhang2023clinicoradiologicsubtypesand pages 1-2, liu2024clinicalanalysisof pages 1-2, singer2023diagnosisandmanagement pages 1-2)

Table: This table summarizes clinically useful, literature-derived facts about Marchiafava-Bignami disease for a disease knowledge base, including phenotypes, MRI patterns, classifications, treatment, and prognosis. It prioritizes recent 2023–2024 evidence while incorporating key quantitative findings from small cohorts and case syntheses.

Notes on PMID requirement

Several key items above come from open-access journals and case reports where the PMID was not available in the retrieved text during this tool run; therefore, DOI/URL and publication dates are provided as stable identifiers instead. (singer2023diagnosisandmanagement pages 1-2, liu2024clinicalanalysisof pages 1-2, zhang2023clinicoradiologicsubtypesand pages 1-2)

References

  1. (singer2023diagnosisandmanagement pages 1-2): Emad Singer, Kinal Bhatt, Adesh Prashad, Larri Rudman, Islam Gadelmoula, and George Michel. Diagnosis and management of marchiafava-bignami disease, a rare neurological complication of long-term alcohol abuse. Discoveries, 11:e168, Jun 2023. URL: https://doi.org/10.15190/d.2023.7, doi:10.15190/d.2023.7. This article has 11 citations.

  2. (liu2024clinicalanalysisof pages 1-2): Cong Liu, Hualong Wang, Bingchuan Xie, Shujuan Tian, and Yan Ding. Clinical analysis of marchiafava-bignami disease. BMC Neurology, Oct 2024. URL: https://doi.org/10.1186/s12883-024-03901-y, doi:10.1186/s12883-024-03901-y. This article has 7 citations and is from a peer-reviewed journal.

  3. (singer2023diagnosisandmanagement pages 4-6): Emad Singer, Kinal Bhatt, Adesh Prashad, Larri Rudman, Islam Gadelmoula, and George Michel. Diagnosis and management of marchiafava-bignami disease, a rare neurological complication of long-term alcohol abuse. Discoveries, 11:e168, Jun 2023. URL: https://doi.org/10.15190/d.2023.7, doi:10.15190/d.2023.7. This article has 11 citations.

  4. (li2021diversemrifindings pages 1-3): Wei Li, Chao Ran, and Jun Ma. Diverse mri findings and clinical outcomes of acute marchiafava-bignami disease. Acta Radiologica, 62:904-908, Jul 2021. URL: https://doi.org/10.1177/0284185120943040, doi:10.1177/0284185120943040. This article has 11 citations and is from a peer-reviewed journal.

  5. (menrai2024anatypicalcase pages 1-2): Devika Menrai, Shyam Kiran Gandam Venkata, Sudeep Chakravarthy Bhuram, and Sai Sruthi Bhuram. An atypical case of marchiafava-bignami disease in a young chronic alcoholic: challenges in diagnosis and prognosis. Cureus, Dec 2024. URL: https://doi.org/10.7759/cureus.75468, doi:10.7759/cureus.75468. This article has 1 citations.

  6. (singer2023diagnosisandmanagement pages 2-4): Emad Singer, Kinal Bhatt, Adesh Prashad, Larri Rudman, Islam Gadelmoula, and George Michel. Diagnosis and management of marchiafava-bignami disease, a rare neurological complication of long-term alcohol abuse. Discoveries, 11:e168, Jun 2023. URL: https://doi.org/10.15190/d.2023.7, doi:10.15190/d.2023.7. This article has 11 citations.

  7. (conceicao2024marchiafavabignamidiseasea pages 1-3): Paulo Conceição, Tânia Lopes, Vasco Abreu, and Ana Reinas. Marchiafava-bignami disease: a case report of a reversible cause of dementia. Cureus, Nov 2024. URL: https://doi.org/10.7759/cureus.73146, doi:10.7759/cureus.73146. This article has 0 citations.

  8. (liu2024clinicalanalysisof pages 2-4): Cong Liu, Hualong Wang, Bingchuan Xie, Shujuan Tian, and Yan Ding. Clinical analysis of marchiafava-bignami disease. BMC Neurology, Oct 2024. URL: https://doi.org/10.1186/s12883-024-03901-y, doi:10.1186/s12883-024-03901-y. This article has 7 citations and is from a peer-reviewed journal.

  9. (conceicao2024marchiafavabignamidiseasea pages 3-4): Paulo Conceição, Tânia Lopes, Vasco Abreu, and Ana Reinas. Marchiafava-bignami disease: a case report of a reversible cause of dementia. Cureus, Nov 2024. URL: https://doi.org/10.7759/cureus.73146, doi:10.7759/cureus.73146. This article has 0 citations.

  10. (zhang2023clinicoradiologicsubtypesand pages 1-2): Yan-li Zhang, Chao Ran, Chao Xu, and Wei Li. Clinico-radiologic subtypes and therapeutic observation of acute marchiafava-bignami disease. Scientific Reports, Oct 2023. URL: https://doi.org/10.1038/s41598-023-45431-6, doi:10.1038/s41598-023-45431-6. This article has 8 citations and is from a peer-reviewed journal.

  11. (singer2023diagnosisandmanagement pages 7-9): Emad Singer, Kinal Bhatt, Adesh Prashad, Larri Rudman, Islam Gadelmoula, and George Michel. Diagnosis and management of marchiafava-bignami disease, a rare neurological complication of long-term alcohol abuse. Discoveries, 11:e168, Jun 2023. URL: https://doi.org/10.15190/d.2023.7, doi:10.15190/d.2023.7. This article has 11 citations.

  12. (conceicao2024marchiafavabignamidiseasea media 16521e3e): Paulo Conceição, Tânia Lopes, Vasco Abreu, and Ana Reinas. Marchiafava-bignami disease: a case report of a reversible cause of dementia. Cureus, Nov 2024. URL: https://doi.org/10.7759/cureus.73146, doi:10.7759/cureus.73146. This article has 0 citations.

  13. (conceicao2024marchiafavabignamidiseasea media 7c11b093): Paulo Conceição, Tânia Lopes, Vasco Abreu, and Ana Reinas. Marchiafava-bignami disease: a case report of a reversible cause of dementia. Cureus, Nov 2024. URL: https://doi.org/10.7759/cureus.73146, doi:10.7759/cureus.73146. This article has 0 citations.

  14. (conceicao2024marchiafavabignamidiseasea media 8bf57d9d): Paulo Conceição, Tânia Lopes, Vasco Abreu, and Ana Reinas. Marchiafava-bignami disease: a case report of a reversible cause of dementia. Cureus, Nov 2024. URL: https://doi.org/10.7759/cureus.73146, doi:10.7759/cureus.73146. This article has 0 citations.

  15. (menrai2024anatypicalcase pages 2-3): Devika Menrai, Shyam Kiran Gandam Venkata, Sudeep Chakravarthy Bhuram, and Sai Sruthi Bhuram. An atypical case of marchiafava-bignami disease in a young chronic alcoholic: challenges in diagnosis and prognosis. Cureus, Dec 2024. URL: https://doi.org/10.7759/cureus.75468, doi:10.7759/cureus.75468. This article has 1 citations.

  16. (cm2017theimportanceof pages 1-3): Pontes Cm, M. Cagy, R. Santos, and Soares Cn. The importance of brain mri in the diagnosis of marchiafava-bignami disease. Journal of Neurology and Neurological Disorders, Aug 2017. URL: https://doi.org/10.15744/2454-4981.3.201, doi:10.15744/2454-4981.3.201. This article has 1 citations.

  17. (NCT06065670 chunk 1): Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy. University of California, San Francisco. 2026. ClinicalTrials.gov Identifier: NCT06065670

  18. (NCT06065670 chunk 4): Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy. University of California, San Francisco. 2026. ClinicalTrials.gov Identifier: NCT06065670